Several recent studies suggest that niclosamide inhibits cancer growth through multiple mechanisms, involving the modulation of Wnt/β-catenin, mTOR, STAT3, NF-kB, and Notch signalling pathways [34,35,36,37] as well as a targeted effect against p53-deficient cancers that is mediated through mitochondrial uncoupling and arachidonic acid-induced apoptosis [17]. Here, NFKB1 is linked to cancer.